TBAJ-876

bedaquiline analog

Networked: 4 relevant articles (1 outcomes, 1 trials/studies)

1.	Upton, Anna M: 2 articles (11/2021 - 10/2019)
2.	Dick, Thomas: 2 articles (01/2020 - 10/2019)
3.	Sarathy, Jickky Palmae: 2 articles (01/2020 - 10/2019)
4.	Almeida, Deepak: 1 article (11/2021)
5.	Converse, Paul J: 1 article (11/2021)
6.	Fotouhi, Nader: 1 article (11/2021)
7.	Li, Si-Yang: 1 article (11/2021)
8.	Nuermberger, Eric L: 1 article (11/2021)
9.	Dartois, Véronique: 1 article (01/2020)
10.	Ganapathy, Uday S: 1 article (01/2020)

1.	Tuberculosis (Tuberculoses) 01/01/2020 - "TBAJ-876, a clinical development candidate of this series, shows attractive in vitro antitubercular activity and efficacy in a murine tuberculosis model. " 10/01/2019 - "TBAJ-876, which is a new developmental compound of this series, shows attractive antitubercular activity and efficacy in a murine tuberculosis model. " 11/17/2021 - "Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis." 01/01/2023 - "We used a well-established BALB/c mouse model of tuberculosis to evaluate the treatment-shortening potential of replacing bedaquiline with either of two new, more potent diarylquinolines, TBAJ-587 and TBAJ-876, in early clinical trials. "
2.	Infections 11/17/2021 - "Likewise, no selective amplification of BDQ-resistant bacteria was observed at TBAJ-876 doses ≥6.25 mg/kg. These results indicate that replacing BDQ with TBAJ-876 may shorten the duration of TB treatment and be more effective in treating and preventing infections caused by Rv0678 mutants." 01/01/2020 - "abscessus infection, demonstrated potent activity in vivo In summary, we demonstrate that TBAJ-876 shows attractive in vitro and in vivo activities against M. "